Early Evidence, The USPSTF Blows – Higher-Risk Prostate Cancers Increase From 2011 to 2013

Between 2011 and 2013, the proportion of men diagnosed with intermediate- or high-risk prostate cancer, increased by 3% per year. Thank you members of the United States Preventive Services Task Force for realy blowing it and tapping in the nail into the coffins of American men. In a preliminary study the authors estimate that this [...]

Prostvac In Combination With Yervoy Yields A Survival Advantage

There is some really exciting news on the horizon around immunotherapy for advanced prostate cancer. Bavarian Nordic, the pharmaseutical company that has, along with the National Cancer Institute (NCI), been running clinical trials on Prostvac has unoffically let it been known that Prostvac when combined with another investigational immunologic therapy, Yervoy, has helped to significantly [...]

Is Cabazitaxel Before Docetaxel The Future Way To Go? *

Chemotherapy for prostate cancer is still limited to just two drugs, docetaxel (Taxotere) and cabazitaxel (Jevtana). Both of these chemotherapy drugs are taxanes, but they seem to be very different in their mode of action. A study published online in Clinical Cancer Research, indicates that cabazitaxel might be more effective for some men than docetaxel. [...]

*Does Avodart (Dutasteride) Allow Men on Intermittent Androgen Therapy To Have A Longer “Off Period”?

Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or to receive a placebo. All of the men were receiving intermittent androgen deprivation therapy (IADT), which was stopped at month [...]

An Evaluation of Testosterone Flare During a Transition from Degarelix to Leuprolide in Men on ADT *

Many men with advanced prostate cancer who are on hormone therapy (ADT) use one of the newer drugs, degarelix (Firmagon) to achieve a state of castration. Degarelix is considered a superior drug for initiating ADT because it is not accompanied with a PSA flare that is common with the older luteinizing hormone-releasing hormone (LHRH) agonists [...]

For Caregivers – Common Signs of Impending Cancer Death

Advanced Prostate cancer will eventually lead to our death. This is a sad truth that I know we all are very aware. In a study published Monday online in Cancer, researchers identify “eight specific physical signs” indicating a patient “with advanced cancer is entering the last days of life.” The signs that were identified were [...]

*Provenge to Survive Dendreon’s Bankruptcy – Welcome Valeant to the Prostate Cancer Community

Dendreon, the manufacture of the only FDA approved immunologic therapy for prostate cancer had been burdened with significant debt. The debt came from their R&D of Provenge, their seeking FDA approval and the construction of three manufacturing plants to produce the treatment. Sadly, the company was unable to get its income ahead of its debt [...]

*After the Failure of Docetaxel Is There A Best Sequence For Other Treatments?: Results of an Italian Multicenter Study

As we all know there are now a number of new drugs available to treat castrate resistant metastatic prostate cancer (mCRPC). The availability of these new drugs (abiraterone acetate aka Zytiga, cabazitaxel aka Jevtana, and enzalutamide aka Xtandi) for use in men with mCRPC after the failure of chemotherapy (with docetaxel) has opened a number [...]

Understanding the Complexities of Bone Metastases in Prostate Cancer

Our bones operate in a balanced and dynamic system, which in the normal situation keep them strong. Bones are constantly being eliminated and then remade to keep them healthy and read to support our frame. This normal process involves two major kinds of bone cells that work together, in balance, to keep bones healthy and [...]

Obama Says “Men, You Don’t Count” As He Eliminates All Prostate Cancer Funding From His Proposed 2016 Budget At The CDC

Men, you don’t count! You have NO VALUE! That is the absolute truth according to President Obama. Just released budget documents from the President proposed budget for 2016 recommends that ALL CDC funding for Prostate Cancer be eliminated! Let me make this clear, no, the President is not recommending that Prostate Cancer funds be cut, [...]

By |2021-02-17T10:29:53-05:00February 5th, 2015|Advanced Prostate Cancer, Screening, Uncategorized|0 Comments
Go to Top